Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 85,947 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Nab-paclitaxel, Carboplatin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee • Seattle, Washington

Conditions: Weight Loss, Pediatric Obesity, Overweight Adolescents, Parent-Child Relations, Family and Household
Interventions: Brenner FIT Standard, By Design Essentials, Dyad Plus; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 13 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Melanoma Neoplasms
Interventions: KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Adhesive Capsulitis, Adhesive Capsulitis of Unspecified Shoulder, Frozen Shoulder
Interventions: Methylprednisolone Injectable Product, Doxycycline Injection; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HER2-positive Gastric Cancer
Interventions: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel, Cinrebafusp alfa (PRS-343) in combination with tucatinib; Drug
Lead sponsor: Pieris Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Santa Barbara, California • Silver Spring, Maryland • New York, New York + 1 more

Conditions: Multiple Sclerosis, Pain, Fatigue Symptom
Interventions: Self-guided smartphone application for relaxing acupressure, Self-guided smartphone application for stimulating acupressure; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Multiple Sclerosis
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Wound Heal
Interventions: Timolol 0.25% Ophthalmic Solution, Standard Wound Care; Drug · Other
Lead sponsor: Keith G. LeBlanc, Jr, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Caries
Interventions: Calcium sodium phosphosilicate, Sodium monoflurophosphate, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
Interventions: Laboratory Biomarker Analysis, Selumetinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis, Cognitive Change, Nutrition, Healthy
Interventions: MIND Diet, Control Diet; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Abdominal Pain
Interventions: Not listed
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
Interventions: Erchonia® EVRL™, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Phoenix, Arizona • West Covina, California • Dunedin, Florida + 1 more

Conditions: Healthy
Interventions: Sitagliptin, atorvastatin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cytomegalovirus Disease
Interventions: Brincidofovir, Valganciclovir; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut

Conditions: Healthy Participants, Mild Cognitive Impairment
Interventions: LLLT, Placebo; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 45 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions: topotecan hydrochloride, cyclodextrin-based polymer-camptothecin CRLX101; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 2 more

Conditions: Colorectal Cancer
Interventions: Panitumumab, Cabozantinib; Biological · Drug
Lead sponsor: John Strickler, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Phase Chronic Myelogenous Leukemia
Interventions: Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily, Imatinib, Nilotinib, Dasatinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Detroit, Michigan • Buffalo, New York • New York, New York + 2 more

Conditions: Breast Cancer
Interventions: Denosumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Uproleselan, Venetoclax; Drug
Lead sponsor: Brian Jonas; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions: Faricimab Injection, sham treatment; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Mitochondrial Diseases
Interventions: Sevoflurane, Dexmedetomidine, Propofol; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Day to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo; Drug · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 907 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 24
States / cities: La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more

Search by objective public record fields.

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Dyad Plus Effectiveness/Feasibility

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Usability of the MeTime MS App

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

Topical Timolol: a Comparison of Surgical Outcomes

Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Remote Evaluation of MIND Diet

Heart Rate Variability in Children With a Functional Gastrointestinal Disorder

Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

Cognitive Enhancement Through Transcranial Laser Therapy

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Denosumab for Breast Cancer With Bone Mets

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Anesthesia in Patients With Mitochondrial Disease

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)